Biora TherapeuticsNASDAQ: BIOR

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced the signing of financing agreements with its existing convertible notes holders. “We appreciate the continued commitment of our existing noteholders, who have agreed to an additional investment in Biora that we expect will fund us to important milestones, including anticipated partnering with large pharma,” said Eric d'Esparbes, Chief Financial Officer of Biora Therapeutics.

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the second quarter ended June 30, 2024. Company management will host a webcast and conference call on Monday, August 12, 2024, after the close of financial markets.

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston. Details of the presentation are as follows: Presentation Title: Empowering Peptide Self Administration with Needle-Free Smart Capsules Track:  Pioneering Devices to Increase the Reach of Peptide APIs Date & Time: Wednesday, June 19, 2024 from 2:15 to 2:45 PM Eastern time Presenting Author: Sharat Singh, PhD, Head of Research, Biora Therapeutics, Inc. Dr. Singh will also participate in a panel discussion on June 19 at 8:45 AM titled “Uncovering Innovations in Peptide Drug Delivery & Formulation for Improved Bioavailability,” alongside representatives from Eli Lilly, Merck, and Novo Nordisk.

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q1 2024 Earnings Conference Call on May 15, 2024 at 4:30 PM ET featuring Chuck Padala, Adi Mohanty, and Eric d'Esparbes. Participants include Joseph Pantginis, Rei Tan, and John Vandermosten. Welcome to Biora Therapeutics' First Quarter 2024 Financial Results Call.

Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Chuck Pedala - LifeSci Advisors Adi Mohanty - CEO Eric d'Esparbes - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright & Co. Julian Harrison - BTIG John Vandermosten - Zacks Investment Research Operator Greetings and welcome to the Biora Therapeutics Third Quarter 2023 earnings call.

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Julian Harrison - BTIG John Vandermosten - Zacks Investment Research Operator Greetings, and welcome to the Biora Therapeutics Second Quarter 2023 Earnings Call.

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report financial results and provide a corporate update for the second quarter ended June 30, 2023. The company's management will host a webcast and conference call on Monday, August 14, 2023, after the close of financial markets at 4:30 PM Eastern time / 1:30 PM Pacific time.

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.